Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GDUFA Success Depends On Industry Changes As Much As Review Improvements, FDA Says

Executive Summary

“This is a shared responsibility. We have to have a shared sense of urgency,” Acting OGD director tells GPhA.


Related Content

New US FDA Generics Director Praises Industry, Encourages Partnerships
Generic Industry Once Again Must Get To Know New US FDA Office Director
Will GDUFA III Curtail Priority Assessments?
Will GDUFA III Curtail Priority Assessments?
FDA Generics Office Gets Third Director In Three Workdays; Uhl Brings Policy, Pharmacology Experience
FDA’s Generics Office Loses Another Director As Geba Makes Quick Exit
Hamburg Trumpets Potential Rewards Of Quality Improvement For Generic Industry
Buying Time: Industry Sacrifices Early To Gain Later With PDUFA V Review Model
Generic Drugs Gain Status Boost Within CDER
Generic User Fee Agreement Includes FDA Pledge To Determine Best Use Of Foreign Regulator Inspections


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts